In 2019, Frier Levitt reported a new dispensing limitation CVS Caremark (“Caremark”) introduced in its retail networks that took effect on January 1, 2020. Specifically, Caremark issued an “Aberrant Product List” that identified... Read More
Pharmacy reimbursement issues and state imposed limits on pharmacist’s scope of practice have been major hurdles to increased COVID-19 testing at pharmacies. The Department of Health and Human Services has now intervened stating that federal... Read More
With the imminent need for information on government action in regards to medical issues and potential lifesaving treatments during the Covid-19 pandemic, various state and federal agencies have seemingly dismissed the public’s right to... Read More
On June 9, 2020 the U.S. Department Health and Human Services (“DHHS”) announced that it was allocating a total of $15 Billion in Provider Relief Fund payments to Medicaid or Children’s Health Insurance Program (CHIP) providers who have been... Read More
If there were ever any doubts about the seriousness of CMS’ commitment to transitioning the nation’s healthcare system from one based on volume-based to value-based compensation models, those doubts were squashed by a recent CMS blog post and... Read More
$50 Billion in Total Funding Available, But Significant Compliance Requirements Must be Satisfied In mid-April, you may have seen a significant payment from the Federal government mysteriously land in your provider bank account. With little notice... Read More
In response to the COVIDI9 crisis, the Secretary of the Department of Health and Human Services invoked his authority to issue blanket waivers of Section 1877(g) of the Social Security Act (also known as the physician self-referral law or... Read More
Since the declaration of a national public health emergency, oral health providers have postponed most non-emergent care, whether as required by state-issued directives, or as recommended by the Interim Guidance for Minimizing Risk of COVID-19... Read More
As part of our firm’s commitment to staying abreast of COVID19-related issues affecting our clients, we are continuing to monitor financial relief program requirements and other important topics. While applying for various forms of aid and... Read More
COVID-19 is having a profound effect on clinical trials for medical products, including drugs, devices and biological products. Site closures, travel restrictions, quarantines, infections among participants and trial personnel, and investigational... Read More
